Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
87 participants
INTERVENTIONAL
2010-06-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• To determine the effects of ketamine, which blocks the ion-channel gated by the NMDA receptor, on performance of cognitive tasks and the extent to which these effects can be reversed by the dopamine receptor antagonist, risperidone.
The secondary objectives of this study are:
* To establish whether patients with schizophrenia are able to reliably complete the biomarker test battery and to assess whether their responses are similar to healthy volunteers treated with ketamine.
* To establish a multi-site recruitment and assessment capacity based on shared Standard Operating Procedures across three study centres.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Healthy volunteers will be identified through advertising and will initially be asked to complete an online questionnaire.Suitability for the next stage of the study will be based on the responses to the online questionnaire. Telephone interviews will then be conducted to assess suitability for screening.Screening visits will then be carried out in which a full medical and lab screening is undertaken. participants will also complete a number of psychiatric questionnaires and interviews. If participants remain suitable they will be invited to an assessment day in which they will be randomised to one of four study medication arms. Participants will then complete the biomarker tasks followed by questionnaires, rating scales and interviews. Patients with schizophrenia will form the 5th study arm and will not receive medication. They will complete the biomarkers in the same way as healthy volunteers.87 participants are planned, 72 healthy volunteers, 15 patients with schizophrenia.
This study does not test any investigational medicinal product (IMP) so any ethical issues that are associated with introducing a participant to a study drug are not applicable in this study.
Ketamine is already a widely used anaesthetic agent but when given at sub-anaesthetic doses is a useful tool for modelling schizophrenia psychosis.
The current study aims to assess the sensitivity of a battery of biomarker tasks (biomarkers are measures of processes that go wrong in illnesses and that contribute to symptoms) to the cognitive deficits induced by ketamine.
It may in future be possible to evaluate the effects of novel treatment for schizophrenia in healthy volunteers using this model, which would then potentially provide a rapid indication of the potential efficacy of candidate compounds at an early phase of drug development .
The study will provide information about the sensitivity of the biomarker tasks in detecting the effects of the pharmacological treatments for schizophrenia in healthy volunteers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ketamine and risperidone
Oral risperidone pretreatment and intravenous ketamine infusion
ketamine
ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
risperidone
risperidone (2 mg) capsule. One dosing of 2 mg.
ketamine and placebo
Oral placebo risperidone pretreatment and intravenous ketamine infusion
ketamine
ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
placebo risperidone
placebo capsule to match risperidone 2 mg capsule
saline and risperidone
Oral risperidone pretreatment and intravenous saline infusion
risperidone
risperidone (2 mg) capsule. One dosing of 2 mg.
saline
saline infusion. Duration approximately 3 hours
saline and placebo
Oral placebo risperidone pretreatment and intravenous saline infusion
saline
saline infusion. Duration approximately 3 hours
placebo risperidone
placebo capsule to match risperidone 2 mg capsule
Patients with Schizophrenia
Patients with schizophrenia will not receive study drug and will not undergo randomisation.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ketamine
ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
risperidone
risperidone (2 mg) capsule. One dosing of 2 mg.
saline
saline infusion. Duration approximately 3 hours
placebo risperidone
placebo capsule to match risperidone 2 mg capsule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fluent English speakers, preferably with English as first language.
* Normotensive with sitting (5 minutes) blood pressure of 100 to 140 mmHg systolic, and 60 to 90 mmHg diastolic.
* Negative alcohol breath test.
* Negative urine drug screen.
* Participant must have consumed only their normal intake of coffee or tea on the morning of the assessment day and not consumed any other beverages containing caffeine for 2 hours prior to the assessment visit.
* Willing to follow the protocol prohibitions and restrictions .
* Participant must have signed the informed consent form.
* Those participants willing to participate in the pharmacogenomic components of the study must have signed the appropriate informed consent form.
* SPQ score of 21 to 36.
* BMI of 18 to 30 kg/m².
* Non-smoker or light smoker (less than 5 cigarettes per day).
* Has not smoked in the 2 hours prior to the assessment visit.
* Females should be surgically sterile or abstinent or practising an effective method of birth control; they should have a negative urine pregnancy test.
* Healthy at screening and assessment visits as determined by the study physician, based on a medical evaluation including medical history, physical examination, laboratory tests, vital signs, 12-lead ECG and pre-study psychological tests.
* Documented history of a diagnosis of schizophrenia as confirmed by GP or psychiatrist or by previous research diagnostic interview.
* Confirmation of diagnosis of schizophrenia, based on the MINI structured clinical interview, carried out by the study physician.
* In good physical health at screening and assessment visits as determined by the study physician, based on a medical evaluation including medical history, physical examination, laboratory tests and vital signs1.
Exclusion Criteria
* Consumption of large amounts of caffeinated drinks.
* Have received over-the-counter medicine within 48 hours prior to assessment visit (apart from paracetamol) unless it will not interfere with the study procedures or compromise safety.
* History of, or current condition of, migraine headaches.
* Significant hearing impairment which in the opinion of the Investigator may interfere with the performance of the psychological test battery.
* Significant visual impairment or history of ocular treatment or ongoing condition which may interfere with the performance of the psychological test battery.
* Participated in a trial with any drug within 84 days of assessment visit.
* Unable or unwilling to comply with study procedures.
* Known or suspected hypersensitivity or intolerance to risperidone or any of their excipients.
* Known or suspected hypersensitivity or intolerance to ketamine or any previous adverse reaction to anaesthesia.
* If female: are pregnant or are trying to get pregnant or are currently breast feeding.
* Relevant history, or presence upon clinical examination, of cardiac, ophthalmologic, gastro-intestinal, hepatic, or renal disease or other condition known to increase risk of side effects.
* History or presence of neurological or psychiatric conditions.
* Have received prescribed medication within 14 days prior to assessment visit (apart from the contraceptive pill) unless it will not interfere with the study procedures or compromise safety.
* Changes to antipsychotic medications within 30 days of assessment visit.
* Admission to hospital, involvement with the home treatment team for psychiatric reasons or documented relapse of psychiatric symptoms within last 3 months.
* History or presence of psychiatric or neurological conditions other than schizophrenia, major depression and generalised anxiety disorder.
* Current extra-pyramidal symptoms and/or adverse effects from antipsychotic medications that, in the opinion of the study physician, will interfere with completion of the study tasks.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cardiff University
OTHER
King's College London
OTHER
P1vital Limited
INDUSTRY
University of Manchester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bill Deakin
Professor of Psychiatry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Professor Bill Deakin
Role: PRINCIPAL_INVESTIGATOR
University of Manchester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Psychiatry, King's College London
London, Greater London, United Kingdom
University of Manchester (Dept of Neuropyschiatry)
Manchester, Manchester, United Kingdom
School of Psychology, University of Cardiff
Cardiff, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P1V-SCH-CT02-09
Identifier Type: -
Identifier Source: org_study_id